Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that time. Stifel argued that Roivant offers multiple late-stage opportunities across specialty autoimmune and pulmonary diseases. The firm projects around $9 billion in ownership-adjusted sales for Roivant by 2037. Can Roivant turn its multi-asset strategy into long-term revenue growth? Anything is possible. Let's dive in.Stifel Sees Roivant (ROIV)’s Sales at $9 Billion by 2037.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.